~~<i id='9B5AD5D2E3'><strike id='9B5AD5D2E3'><tt id='9B5AD5D2E3'><pre id='9B5AD5D2E3'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：knowledge 2025-10-01 08:24:50 Page View：61336

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Can medical device makers keep up in the race to treat obesity?
Next article： Medical records are filled with copy

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

FDA approves first new drug developed for postpartum depression

AdobeTheFoodandDrugAdministrationonTuesdayapprovedbrexanolone,thefirstdrugspecificallytargetedtotrea

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Senate panel passes drug pricing bills, but drops one PBM reform

CommitteeRankingRepublicanBillCassidy(La.)andChairmanBernieSanders(I-Vt.)ChipSomodevilla/GettyImages

WSS

knowledge

knowledge

Wikipedia

explore

Senate panel passes drug pricing bills, but drops one PBM reform